Probuphine · DIN 02474921 · 80 mg · Subdermal Implant-Kit Pk
Limited Use, Reason for Use code 578 required; Health Canada lists this DIN as Cancelled post market since 2023-06-30 — choose a marketed DIN from the same-category list.Discontinued June 30, 2023 · checked November 18, 2026
StatusLimited Use, Reason for Use code 578 required; Health Canada lists this DIN as Cancelled post market since 2023-06-30 — choose a marketed DIN from the same-category list.
Write on scriptReason for Use code 578 (criteria below); Health Canada lists this DIN as Cancelled post market since 2023-06-30 — choose a marketed DIN from the same-category list.
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 578
Reason for Use code 578
For the management of opioid use disorder in combination with counseling and psychosocial support in adult patients who meet the following criteria:
- The patient is stabilized on a dose of no more than 8mg per day of sublingual buprenorphine for the preceding 90 days; AND
- The patient is under the care of a health care provider with experience in the diagnosis and management of opioid use disorder and has been trained to implant and remove the buprenorphine subdermal implant.
Recommended dose: Four 80mg implants inserted subdermally in the inner side of the upper arm for up to six months.
The maximum quantity that can be claimed per patient is four (4) implant cycles (i.e. two (2) years of therapy).
NOTE: The product monograph indicates that dosing beyond two (2) years cannot be recommended at this time. Probuphine subdermal implants are intended to be in place for six months of treatment. Probuphine implants are removed at the end of the six-month period. If continued treatment is desired, the implants should be replaced by new implants (implanted in the opposite arm) at the time of removal.
Coverage limit:
LU Authorization Period: 2 years
No interchangeable product listed in the Ontario extract
Probuphine · DIN 02474921
Manufacturer: Knight Therapeutics Inc.; listing date 2020-04-30
Health Canada: Cancelled post market since 2023-06-30 · brand PROBUPHINE · ATC N07BC01 BUPRENORPHINE · form Implant · route Subcutaneous · ingredients BUPRENORPHINE HYDROCHLORIDE 80 MG · company Knight therapeutics inc. · schedule Narcotics (cdsa i)
Probuphine: Formulary list price $1495.00 per unit (the source does not state the unit; exact figure $1495.0000). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02474921)
Source record
DIN 02474921: Probuphine
Raw flags: sec12=Y, sec3=Y
Item: 280812023; group id 416; item number 1027; lccId 00333; manufacturer id KNT
Source form: Subdermal Implant-Kit Pk; strength: 80mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1495.0000; ministry $1495.0000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02474921
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96515
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since June 30, 2023 — choose a marketed DIN from the same-category list.